The effect of botulinum toxin on hand function after incomplete spinal cord injury at the level of C5/6: A case report

Clinical Rehabilitation

Volumn 11, Issue 4, 1997, Pages 288-292

  Richardson, D ^a   Edwards, S ^a   Sheean, G L ^a   Greenwood, R J ^a   Thompson, A J ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; ELECTROMYOGRAPHY; GRIP STRENGTH; HAND FUNCTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; SPASTICITY; SPINAL CORD INJURY;

EID: 0030663718     PISSN: 02692155     EISSN: None     Source Type: Journal    
DOI: 10.1177/026921559701100404     Document Type: Article

References (15)

1. Lance JW. Pathophysiology of spasticity and clinical experience with baclofen. In: Feldman RG, Young RR, Koella WP eds. Spasticity: Disordered motor control. London: Year Book Medical Publishers, 1980: 185-204.
2. Brown P. Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry 1994; 57: 773-77
3. Edwards S. The incomplete spinal cord injury. In: Bromley Ida ed. Tetraplegia and paraplegia: a guide for physiotherapists. Edinburgh: Churchill Livingstone. 1991: 145-66.
4. Dietz V, Quintern J, Berger W. Electrophysiological studies of gait in spasticity and rigidity: Evidence that altered mechanical properties of muscle contribute to hypertonia. Brain 1981; 104: 431-49.
5. Berger W, Horstmann G, Dietz V. Tension development and muscle activation in the leg during gait in spastic hemiparesis: Independence of muscle hypertonia and exaggerated stretch reflexes. J Neurol Neurosurg Psychiatry 1984; 47: 1029-33.
6. Stevenson VL, Playford ED, Langdon DW, Thompson AJ. Rehabilitation of incomplete spinal cord pathology: factors affecting prognosis and outcome. J Neurol 1996; 243: 644-47.
7. Simpson DM. Alexander DN, O'Brien CF et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46(5): 1306-10.
8. Dengler R, Neyer U, Wohifarth K, Bettig U. Janzik HH. Local botulinum toxin in the treatment of spastic drop foot. J Neurol 1992; 239(7): 375-78.
9. Anderson TJ, Donaldson IM, Botulinum toxin; one man's poison is another man's potion. N Z Med J 1995; 108: 307-308
10. Hesse S, Krajnik J, Luecke D, Jahnke MT. Gregoric M. Mauritz KH. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 1996; 27(3): 455-60.
11. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip and pinch strength evaluations. J Hand Surg Am 1984; 92: 222-26.
12. Ashworth B. Preliminary trial of cariosoprodal in multiple sclerosis. Practitioner 1964; 192: 540.
13. Norkin CC. White DJ. Measurement of joint motion. A guide to gontometry, second edition. Philadelphia: FA Davies: 1995.
14. Jebsen RH. Trieschmann R, Trotter N, Howard LA. An objective and standardised test of hand function. Arch Phys Rehabil 1969; 50: 311-19.
15. Lincoln NB, Leadbetter D. Assessment of motor function in stroke patients. Physiotherapy 1979; 65: 48-51.